Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial (vol 385, 1087, 2015)

被引：0
|
作者：
Sulkowski, M.
Hezode, C.
Gerstoft, J.
机构：
来源：
LANCET | 2015年 / 385卷 / 9973期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1074 / 1074
页数：1
相关论文
共 50 条
  • [21] THE PHASE 3 C-EDGE TREATMENT-NAIVE (TN) STUDY OF A 12-WEEK ORAL REGIMEN OF GRAZOPREVIR (GZR, MK-5172)/ELBASVIR (EBR, MK-8742) IN PATIENTS WITH CHRONIC HCV GENOTYPE (GT) 1, 4, OR 6 INFECTION
    Zeuzem, S.
    Ghalib, R.
    Reddy, K. R.
    Pockros, P. J.
    Ari, Z. B.
    Zhao, Y.
    Brown, D.
    DiNubile, M.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Butterton, J.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S213 - S213
  • [22] Sofosbuvir and ledipasvir for 8 weeks in patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 1 and 4 in clinical practice - Results from the GErman hepatitis C COhort (GECCO)
    Christensen, Stefan
    Mauss, Stefan
    Hueppe, Dietrich
    Schewe, Knud
    Lutz, Thomas
    Rockstroh, Juergen K.
    Schuetze, Marcel
    Schmutz, Guenther
    Simon, Karl-Georg
    Busch, Heiner W.
    Ingiliz, Patrick
    Baumgarten, Axel
    HEPATOLOGY, 2015, 62 : 740A - 741A
  • [23] Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection
    Howe, Anita Y. M.
    Black, Stuart
    Curry, Stephanie
    Ludmerer, Steven W.
    Liu, Rong
    Barnard, Richard J. O.
    Newhard, William
    Hwang, Peggy M. T.
    Nickle, David
    Gilbert, Christopher
    Caro, Luzelena
    DiNubile, Mark J.
    Mobashery, Niloufar
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (12) : 1657 - 1665
  • [24] High Efficacy in Patients With Chronic Hepatitis C Virus (HCV) Genotype (GT) 1b Infection Treatment With Elbasvir/Grazoprevir for 12 Weeks: An Integrated Analysis
    Zeuzem, Stefan
    Serfaty, Lawrence
    Vierling, John M.
    Cheng, Wendy
    George, Jacob
    Sperl, Jan
    Strasser, Simone I.
    Kumada, Hiromitsu
    Hwang, Peggy
    Robertson, Michael
    Wahl, Janice
    Barr, Eliav
    Talwani, Rohit
    Platt, Heather L.
    HEPATOLOGY, 2016, 64 : 433A - 433A
  • [25] C-SWIFT: GRAZOPREVIR/ELBASVIR plus SOFOSBUVIR IN CIRRHOTIC AND NONCIRRHOTIC, TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION, FOR DURATIONS OF 4, 6 OR 8 WEEKS AND GENOTYPE 3 INFECTION FOR DURATIONS OF 8 OR 12 WEEKS
    Poordad, F.
    Lawitz, E.
    Gutierrez, J. A.
    Evans, B.
    Howe, A.
    Feng, H. -P.
    Li, J. J.
    Hwang, P.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Haber, B.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S192 - S193
  • [26] Efficacy of 8 Weeks Versus 12 Weeks of Elbasvir/ Grazoprevir in Treatment-Naive Chronic Hepatitis C Genotype 1b Patients with Mild Fibrosis: An Open-Label, Randomized, Active Control Trial (EGALITE)-Interim Report
    Yu, Ming-Lung
    Hung, Chao-Hung
    Cheng, Pin-Nan
    Bair, Ming-Jong
    Kao, Jia-Horng
    Huang, Yi-Hsiang
    Lee, Pei-Lun
    Chien, Rong-Nan
    Peng, Cheng-Yuan
    Hsieh, Tsai-Yuan
    Lin, Chun-Yen
    Dai, Chia-Yen
    Huang, Jee-Fu
    Huang, Chung-Feng
    Chuang, Wan-Long
    HEPATOLOGY, 2018, 68 : 595A - 596A
  • [27] SAFETY AND EFFICACY OF MK-5172 PLUS PEGINTERFERON ALFA-2b AND RIBAVIRIN (PR) IN CIRRHOTIC AND NON-CIRRHOTIC TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE (G)1 INFECTION
    Hezode, C.
    Bruno, S.
    Jacobson, I.
    Serfaty, L.
    Kwo, P.
    Zhou, A.
    Gilbert, C.
    Hwang, P.
    Wahl, J.
    Robertson, M. N.
    Mobashery, N.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S500 - S500
  • [28] Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
    Lawitz, Eric
    Reau, Nancy
    Hinestrosa, Federico
    Rabinovitz, Mordechai
    Schiff, Eugene
    Sheikh, Aasim
    Younes, Ziad
    Herring, Robert, Jr.
    Reddy, K. Rajender
    Tram Tran
    Bennett, Michael
    Nahass, Ronald
    Yang, Jenny C.
    Lu, Sophia
    Dvory-Sobol, Hadas
    Stamm, Luisa M.
    Brainard, Diana M.
    McHutchison, John G.
    Pearlman, Brian
    Shiffman, Mitchell
    Hawkins, Trevor
    Curry, Michael
    Jacobson, Ira
    GASTROENTEROLOGY, 2016, 151 (05) : 893 - +
  • [29] Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
    Manns, Michael
    Samuel, Didier
    Gane, Edward J.
    Mutimer, David
    McCaughan, Geoff
    Buti, Maria
    Prieto, Martin
    Luis Calleja, Jose
    Peck-Radosavljevic, Markus
    Mullhaupt, Beat
    Agarwal, Kosh
    Angus, Peter
    Yoshida, Eric M.
    Colombo, Massimo
    Rizzetto, Mario
    Dvory-Sobol, Hadas
    Denning, Jill
    Arterburn, Sarah
    Pang, Phillip S.
    Brainard, Diana
    McHutchison, John G.
    Dufour, Jean-Francois
    Van Vlierberghe, Hans
    van Hoek, Bart
    Forns, Xavier
    LANCET INFECTIOUS DISEASES, 2016, 16 (06): : 685 - 697
  • [30] Effect of peginterferon alpha-2b and ribavirin on histological lesions in patients with hepatitis C virus (HCV) and HCV/HIV co-infection:: An open-label trial
    Sarmento e Castro, R.
    Horta, A.
    Coelho, H.
    Vasconcelos, O.
    Mendez, J.
    Seabra, J.
    Tavares, A. P.
    Fortes, O.
    Duarte, M.
    Pires, N.
    Chaves, L.
    Pires, J. P.
    Pinho, L.
    Carneiro, F.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S225 - S225
12345